Science & Pipeline
Roca Therapeutics aims to be a holistic disease-driven company addressing neovascular retinal diseases.
Redefining severe retinal disease care with a disease-modifying first-in-class topical therapy to treat radiation maculopathy as a first indication with quick follow expansion into diabetic macular edema.
Our Science
Roca Therapeutics’ novel approach for ocular diseases is based on over a decade of foundational scientific research across medicinal chemistry, oncology, ophthalmology and immunology from the co-founders Dr. Gilles Pagès, Dr. Maeva Dufies, Dr. Cyril Ronco and Dr. Rachid Benhida.
We are advancing our lead translational research program, RCT002, as building blocks towards a promising portfolio of patent protected first-In-class small molecules.
Our objective is to address exacerbated/resistant mechanisms of angiogenesis, chronic inflammation and oxidative stress in the context of neoplastic and neovascular disorders.
Our Pipeline
Roca Therapeutics is a holistic disease-driven company addressing radiation maculopathy with lead drug candidate, RCT002. Beyond radiation maculopathy, RCT002’s unique MOA positions it as a quick follow expansion opportunity for diabetic macular edema.
Designed for severe highly aggressive neovascular retinal diseases
Our lead candidate, RCT002, recently received orphan drug designation from the EMA and is less than 12 months from IND/CTA submission and has shown promising efficacy and pharmacological data. Developed for topical administration, RCT002 offers a unique product profile. With a non-invasive route of administration, RCT002 modifies disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis.
RCT002 is backed by solid translational and mechanistic data. We have designed a robust disease, clinical, and regulatory strategy targeting radiation-induced maculopathy (an orphan disease) and diabetic macular edema as a target second indication.
Ecosystem & Partners
